Nonadherence to guideline-directed anticoagulations in atrial fibrillation in Iraq

Abstract EN

Background: Anticoagulations remain an essential step to minimize the mortality and morbidity associated with thromboembolic phenomena in atrial fibrillation (AF).

Nevertheless, the adherence to OAC stands for (Oral Anticoagulant) throughout the paper is not universal among the different populations.

In Iraq, there are no data about adherence to (OAC) in patients with AF.

Objectives: This study aimed to assess the adherence to oral anticoagulants (OAC) based on the American College of Cardiology/American Heart Association performance measures in eligible patients with a CHA2DS2 ‑VASc ≥2 in patients with AF in Duhok, Iraq.

Materials and Methods: A total of 132 patients who were diagnosed with AF were consecutively reviewed during 2018–2019 in Azadi Teaching Hospital, Duhok, Kurdistan Region, Iraq.

For eligibility of taking an OAC, the VAS score derived from CHA2 DS2 ‑VASc for all patients was calculated.

Results: The mean age of the patients was 65.29 (standard deviation [SD]: 17.18 years).

The average duration of AF was (2.0) years.

The mean of VAS score was 2.97 (SD: 1.75, ranged between 0 and 8.0).

78.0% of all patients were eligible for OAC at admission.

Only 15.9% of the patients were on OAC.

In the logistic regression analysis, none of the patient's characteristics predict significantly the nonadherence to OAC.

Conclusion: The present study showed that a high percentage of AF patients were eligible for OAC.

However, only a small percentage of them were receiving OAC at admission in our Background: Anticoagulations remain an essential step to minimize the mortality and morbidity associated with thromboembolic phenomena in atrial fibrillation (AF).

Nevertheless, the adherence to OAC stands for (Oral Anticoagulant) throughout the paper is not universal among the different populations.

In Iraq, there are no data about adherence to (OAC) in patients with AF.

Objectives: This study aimed to assess the adherence to oral anticoagulants (OAC) based on the American College of Cardiology/American Heart Association performance measures in eligible patients with a CHA2DS2 ‑VASc ≥2 in patients with AF in Duhok, Iraq.

Materials and Methods: A total of 132 patients who were diagnosed with AF were consecutively reviewed during 2018–2019 in Azadi Teaching Hospital, Duhok, Kurdistan Region, Iraq.

For eligibility of taking an OAC, the VAS score derived from CHA2 DS2 ‑VASc for all patients was calculated.

Results: The mean age of the patients was 65.29 (standard deviation [SD]: 17.18 years).

The average duration of AF was (2.0) years.

The mean of VAS score was 2.97 (SD: 1.75, ranged between 0 and 8.0).

78.0% of all patients were eligible for OAC at admission.

Only 15.9% of the patients were on OAC.

In the logistic regression analysis, none of the patient's characteristics predict significantly the nonadherence to OAC.

Conclusion: The present study showed that a high percentage of AF patients were eligible for OAC.

However, only a small percentage of them were receiving OAC at admission in our area.